Enjoy complimentary customisation on priority with our Enterprise License!
The osteoporosis drugs market share is expected to increase by USD 5.11 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 9.64%.
This osteoporosis drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers osteoporosis drugs market segmentation by product (antiresorptive drugs and anabolic drugs) and geography (North America, Europe, Asia, and ROW). The osteoporosis drugs market report also offers information on several market vendors, including Amgen Inc., Asahi Kasei Corp., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd., and UCB SA among others.
Download the Free Report Sample to Unlock the Osteoporosis Drugs Market Size for the Forecast Period and Other Important Statistics
"As per the World Bank Group and the National Institutes of Health (NIH), the incidence of the geriatric population at a global level is expected to grow from 8.48% in 2016 to approximately 17% by 2050."
The availability of guidelines for disease management is notably driving the osteoporosis drugs market growth, although factors such as high cost of treatment may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the osteoporosis drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Osteoporosis Drugs Market Driver
The available guidelines for disease management is one of the key drivers for the osteoporosis drug market share growth. It is a mandate for physicians to adopt evidence-based recommendations to their patients due to an increase in global incidences of osteoporosis. The guidelines for disease management are framed as per scientific evidence and adopted based on several factors such as the needs of patients and previous and ongoing therapies. Moreover, there is a number of international organizations developing models to ensure optimal delivery of recommended osteoporosis therapies in healthcare systems. Thus, the guidelines are expected to contribute to the osteoporosis drugs market growth during the forecast period.
Key Osteoporosis Drugs Market Challenge
The high costs of treatment is a key challenge for the growth of the osteoporosis drugs market vendors. Treatment goals are often to reduce pain and improve functions as no therapy has the potential to reverse joint damage, resulting in life-long expenses for treating diseases and preventing symptoms using drugs. Moreover, the cost of treatments differs across regions, depending on several health condition factors. According to the CDC, osteoporosis is the second most health condition treated globally. Thus, the imposition of a high financial burden on patients as well as healthcare systems is expected to hinder the osteoporosis drugs market growth during the forecast period.
This osteoporosis drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
The parent market, the global pharmaceuticals market, covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the osteoporosis drugs market encompasses successful business strategies deployed by the key vendors. The osteoporosis drugs market is fragmented and the vendors are deploying growth strategies such as collaborations and adopting license agreements to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The osteoporosis drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.